AstraZeneca PLC
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Oncology — US product sales: $11,187M in FY2025, up 17.6% from a year earlier.
Latest, FY2025
11,187
Period ended Dec 31, 2025
Change on a year earlier
+17.6%
9,510 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Where the FY2025 figure comes from
“|| Oncology | 23,698 | 17 | 16 | 11,187 | 18 | 5,350 | 19 | 21 | 4,880 | 20 | 15 | 2,281 | 5 | 5”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Therapy Area Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11,187 | +17.6% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 9,510 | +23.2% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 7,719 | +19.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 6,484 | +21.0% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 5,359 | +26.1% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 4,250 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up oncology — US product sales
Cite this data
StockData. (2026). AstraZeneca Oncology — US product sales ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-oncology-us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.